Physician Resources

 

 

  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Juvenile idiopathic arthritis
  • Psoriasis
  • Hidradenitis suppurativa
  • Others

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data

Kapoor S, Kaushik VV, Jain R, Rao V, Gharia M
Rheumatology and Therapy, September 2019, Volume 6, Issue 3, pp 451–459

Real-life efficacy and tolerability profile of a similar biologic of adalimumab (ZRC-3197) in patients with inflammatory arthritic conditions

Viswanath V. Kaushik, Rheumatology, Arthritis & Rheumatism Centre, Chennai, Tamilnadu India
Oxford Rheumatology, April/2018/57(3)

Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases

Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)

Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis : A Real-life Experience

Banwari Sharma
Journal of The Association of Physicians of India, May/2017/65(5)

Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions

V. Kaushik, S. Apparao
Annals of the Rheumatic Diseases, June/2017/76(2)

Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions

A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)

A prospective, randomized, double-blind, multicenter, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (ExemptiaTM; ZRC-3197) and adalimumab (Humira®) in patients with rheumatoid arthritis

Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, Gaurav Rathi, Patnala Ashok Kumar, Reena sharma, Uma Kumar, Liyakat A. Gauri, Praveen Jadhav, Girishchandra Bartakke, Vikram Haridas, Dinesh Jain and Sanjeev K. Mendiratta
International Journal of Rheumatic Diseases, Volume 19 | Number 11 | November 2016

Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab biosimilar Patient Registry Data

Sanjiv Kapoor, Viswanath V. Kaushik, Rahul Jain, Vijay K. R. Rao, and Mihir Gharia
ACR Open Rheumatology Journal, Early Access August 12, 2019

Prolonged effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)

Arvind Chopra, Nagnath Khadke, Manjit Saluja, Toktam Kainifard and Anuradha Venugopalan
Arthritis Rheumatol. 2018; 70 (suppl 10)

Efficacy and safety of an altered dose of biosimilar adalimumab after the initial recommended therapy in patients with ankylosing spondylitis

S. Bandyopadhyay; S. Ghosh, Apollo Gleneagles Hospital, Kolkata, India
International Journal Of Rheumatic Disease, September/2018/Volume 21, Issue S1

Real-life efficacy and tolerability profile of a similar biologic of adalimumab (ZRC-3197) in patients with inflammatory arthritic conditions

Viswanath V. Kaushik, Rheumatology, Arthritis & Rheumatism Centre, Chennai, Tamilnadu India
Oxford Rheumatology, April/2018/57(3)

Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases

Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)

Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy : A Prospective Evaluation from Real-Life Clinical Practice

Sanjiv Kapoor
Journal of The Association of Physicians of India, May/2017/65(5)

Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis : A Real-life Experience

Banwari Sharma
Journal of The Association of Physicians of India, May/2017/65(5)

Continued effectiveness of a biosimilar adalimumab after stoppage of initial treatment in patients with ankylosing spondylitis

S. Bandyopadhyay, A. Ray, R. N. Sarkar, S. Dash, S. Mondal
Annals of the Rheumatic Diseases, June/2017/76(2)

Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions

V. Kaushik, S. Apparao
Annals of the Rheumatic Diseases, June/2017/76(2)

Improvement in disease activity and functional disability following treatment with biosimilar adalimumab in patients with ankylosing spondylitis

VK Rao, A Sudhakar
International Journal of Rheumatic Disease, October/2017/20(1)

Comparison of efficacy of Biosimilar Adalimumab therapy in Ankylosing Spondylitis patients - 6 months Vs 1 year

S. Bandyopadhyay, A. Ray, R. N. Sarkar, S. Dash, S. Mondal
International Journal of Rheumatic Disease, October/2017/20(1)

Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions

A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)

Efficacy and Safety of Adalimumab Biosimilar (ExemptiaTM) in Ankylosing Spondylitis

S. Bandyopadhyay, A. Ray, R. Sarkar
International Journal of Rheumatic Diseases, September/2016

Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases

Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)

Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions

A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)

Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases

Ashish J Mathew, Arvind Ganapati, Sathish Kumar T1, Ruchika Goel, Sandhya P, Debashish Danda
Journal of The Association of Physicians of India, May/2017/65(5)

Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (ExemptiaTM) in patients with various inflammatory arthritis conditions

A. Badika, HOD Rheumatology, Choithram Hospital and Research Centre, Indore
International Journal of Rheumatic Disease, October/2017/20(1)

Use, Safety and Efficacy of ZRC 3197, a Biosimilar Candidate for Reference Adalimumab (Humira®) from a Tertiary Pediatric Rheumatology Centre in India

Manjari Agarwa, Abhay Shivpuri, Sumidha Mittal, Amit Khosla and Sujata Sawhney
Arthritis & Rheumatology, November/2016/68(10)

Real-life efficacy and safety of biosimilar adalimumab (zrc-3197) in patients with plaque psoriasis: A tertiary care center experience

Ajay Chopra, Debdeep Mitra, Reetu Agarwal, Neerja Saraswat, Pooja Chemburkar, Loknandini Sharma
Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India

Indian Dermatol Online J [Epub ahead of print] [cited 2020 Jan 31]. Available from http://www.idoj.in/preprintarticle.asp?id=276544

Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa

Sharmila Patil, Department of Dermatology, Dr. DY Patil Hospital, Navi Mumbai, Maharashtra, India
Indian Journal of Dermatology, Venereology and Leprology, Oct/2018/84(6)

Reduced Injection Site Pain with Succinate Buffer‑Based Adalimumab Biosimilar (ZRC‑3197) Injection (SUFFER Study): An Observational Study

Mihir Gharia, Sudhakar A, Zydus Biovation, Zydus Cadila Healthcare Ltd.
Indian Journal of Rheumatology, Jun/2019/14

A Case of Relapsing Polychondritis with Stenosis Successfully Controlled with Biosimilar Adalimumab (ZRC‑3197)

Dugar M, Saluja JS, Sudhakar A
Indian J Rheumatol. 2019;14:81-82

A Case of Isotretinoin Therapy‑Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (ExemptiaTM)

Furtado Shireen, A Sudhakar
International Journal of Trichology, Dec/2018/10(5)

Reduced injection site pain with succinate buffer based Adalimumab biosimilar injection (SUFFER Study) : An observational study

Mihir Gharia, Sudhakar A
Indian Journal of Rheumatology, November/2016

Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197

Sanjay Bandyopadhyay, Mukesh Mahajan, Tulsi Mehta, Arun K Singh, Aashini Parikh, Ajit K Gupta, Pankaj Kalita, Mihir Patel, Sanjeev Kumar Mendiratta
Biosimilars. 2015;5:1-18